Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that Wild type ALK status confers therapeutic sensitivity to Atezolizumab, Carboplatin, Nab-paclitaxel in patients with Non-Small Cell Lung Cancer.
The European Medicines Agency (EMA) has authorized atezolizumab in combination with nab-paclitaxel and carboplatin for the first-line treatment of adult patients with metastatic non-squamous non-small cell lung cancer (NSCLC) who do not have EGFR mutant or ALK-positive NSCLC.
This statement is based on a regulatory approval from the European Medicines Agency:
Tecentriq, in combination with nab-paclitaxel and carboplatin, is indicated for the first-line treatment of adult patients with metastatic non-squamous NSCLC who do not have EGFR mutant or ALK-positive NSCLC.